The Pharma Data

DECEMBER 8, 2020

RayzeBio is also funneling cash into expanding its HQ in San Diego with plans to further develop internal R&D. . Pear’s reSET, reSET-O and Somryst are the first PDTs to receive FDA approval for treating disease. SciNeuro Pharmaceuticals . Headquartered in Shanghai, the company will also have a hub in Philadelphia.

RNA 52

RNA Protein Expression Therapies Disease 52

Agency IQ

NOVEMBER 3, 2023

One non-profit organization, the International Society Association for Probiotics and Prebiotics (ISAPP) , which is dedicated to promoting research in this area, has published consensus statements that have helped to define some of these terms and their associated substances. To do this, it provides both a probiotic and a prebiotic.

Therapies 40

Therapies Science FDA Production 40

The Pharma Data

NOVEMBER 5, 2020

FDA accepted for priority review Libtayo ® (cemiplimab-rwlc) for both advanced non-small cell lung cancer and basal cell carcinoma. FDA approved Inmazeb for Ebola ( Zaire ebolavirus). R&D: Up-front payments related to license and collaboration agreements. (85). Regeneron Pharmaceuticals, Inc. Oncology Program.

Production 52

Production FDA FDA Approval Trials 52

The Pharma Data

JANUARY 21, 2021

CABENUVA, a co-packaged kit with two injectable medicines, offers people living with HIV a new approach for maintaining viral suppression. Click to Tweet : #BREAKING: The #FDA has approved another treatment option for people living with #HIV. . Global Head, Janssen Research & Development, Johnson & Johnson.

FDA Approval 52

FDA Approval Treatment RNA FDA 52

The Pharma Data

AUGUST 6, 2020

See “Worldwide Pro Forma Revenue” in Quarterly Package of Financial Information for this quarter, which is available on bms.com/investors/financial-reporting/quarterly-results, for information on the revenue of the company and Celgene on a stand-alone basis for the prior-year period. International revenues increased 40% to $3.6

Production 52

Production International Licensing Licensing 52

The Pharma Data

AUGUST 3, 2021

Food and Drug Administration (FDA) approved LUMAKRAS for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. In May, the U.S. Tezepelumab. XmAb is a registered trademark of Xencor, Inc.

Biosimilars 52

Biosimilars Production Treatment FDA 52

Agency IQ

JUNE 16, 2023

0910-AI78 June 2023 May 2023 Final Rule Stage Sunlamp Products; Amendment to the Performance Standard FDA is updating the performance standard for sunlamp products and ultraviolet lamps intended for use in these products to improve safety, reflect new scientific information, and work towards harmonization with international standards.

Regulations 40

Regulations FDA Science Production 40